Detected ·
Ratio Therapeutics
$70M—
Ratio Therapeutics raised $70M in a Series C round, bringing total capital raised to over $240M. The funding will advance its ATLAS study evaluating lead asset [Ac-225]RTX-2358 in advanced sarcomas, move its next-gen RLT candidate into the clinic, and scale manufacturing at its vertically integrated site in Utah. Investors include Duquesne Family Office, Bristol Myers Squibb, Catalio Capital Management, Eli Lilly, and Wasatch Group.
- Website
- ratiotx.com
- Amount
- $70 000 000 USD
- Stage
- —
- Event
- Funding round
- Detected
- 2026-08-02 16:02:07 UTC
- Signal ID
- 899730e0-f3b4-4019-bad2-8edc8b3ec36f
As the API returns it
{
"id": "899730e0-f3b4-4019-bad2-8edc8b3ec36f",
"created_at": "2026-08-02T16:02:07.063137Z",
"company_name": "Ratio Therapeutics",
"company_website_url": "ratiotx.com",
"company_linkedin_url": "https://www.linkedin.com/company/ratio-therapeutics",
"event_type": "funding",
"funding_amount": 70000000,
"funding_currency": "USD",
"funding_stage": null,
"message": "*Ratio Therapeutics raised $70M in a Series C round, bringing total capital raised to over $240M. The funding will advance its ATLAS study evaluating lead asset [Ac-225]RTX-2358 in advanced sarcomas, move its next-gen RLT candidate into the clinic, and scale manufacturing at its vertically integrated site in Utah. Investors include Duquesne Family Office, Bristol Myers Squibb, Catalio Capital Management, Eli Lilly, and Wasatch Group.*"
}